Abstract
ZAP-70 tyrosine kinase is involved in signalling pathways following T-cell receptor stimulation and was originally described only in T cells and natural killer cells. ZAP-70 expression has been reported in normal mouse B lineage cells and in human malignant B lymphocytes, mainly in chronic lymphocytic leukemia (CLL) where it correlates with clinical outcome. We analyzed several B-cell lines and ex vivo malignant B cells, ranging from acute lymphoblastic leukemia to multiple myeloma and reflecting different stages of B-cell differentiation, and they showed ZAP-70 expression regardless their maturation stage. We then analyzed by Western blot and flow cytometry different human normal B-lymphocyte subpopulations: naïve, germinal center and memory B cells from tonsils, CD19+ CD5+ cells from cord blood and CD19+ lymphocytes from peripheral blood. All expressed ZAP-70 protein, though at different levels depending on their differentiation, activation and tissue localization. In addition, ZAP-70 expression levels could be modulated following stimulation via the B-cell receptor. These findings implicate a potential role of ZAP-70 in the signalling pathway of B lymphocytes at different maturational stages, indicate that ZAP-70 expression is not a CLL-specific feature among B-cell malignancies and suggest that the absence of ZAP-70 rather than its presence should be considered abnormal for malignant B lymphocytes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Profiling of human lymphocytes reveals a specific network of protein kinases modulated by endurance training status
Scientific Reports Open Access 21 January 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout




References
Chan AC, Iwashima M, Turck CW, Weiss A . ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992; 71: 649–662.
Law CL, Sidorenko SP, Chandran KA, Draves KE, Chan AC, Weiss A et al. Molecular cloning of human Syk. A B cell protein-tyrosine kinase associated with the surface immunoglobulin M-B cell receptor complex. J Biol Chem 1994; 269: 12310–12319.
Chan AC, van Oers NS, Tran A, Turka L, Law CL, Ryan JC et al. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol 1994; 152: 4758–4766.
Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951, [E-pub 2003 Feb 4920].
Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609–4614, E-pub 2002 Aug 4608.
Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775.
Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111.
Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005; 105: 2036–2041.
Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647.
Schweighoffer E, Vanes L, Mathiot A, Nakamura T, Tybulewicz VL . Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003; 18: 523–533.
Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF . ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005; 19: 1018–1024.
Carreras J, Villamor N, Colomo L, Moreno C, Ramon y CS, Crespo M et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005; 205: 507–513.
Sup SJ, Domiati-Saad R, Kelley TW, Steinle R, Zhao X, Hsi ED . ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL. Am J Clin Pathol 2004; 122: 582–587.
Admirand JH, Rassidakis GZ, Abruzzo LV, Valbuena JR, Jones D, Medeiros LJ . Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol 2004; 17: 954–961.
Guillaume N, Alleaume C, Munfus D, Capiod JC, Touati G, Pautard B et al. ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells. Haematologica 2005; 90: 899–905.
Kantor A . A new nomenclature for B cells. Immunol Today 1991; 12: 388.
Ghia P, Boussiotis VA, Schultze JL, Cardoso AA, Dorfman DM, Gribben JG et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998; 91: 244–251.
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901.
Alessio M, De Monte L, Scirea A, Gruarin P, Tandon NN, Sitia R . Synthesis, processing, and intracellular transport of CD36 during monocytic differentiation. J Biol Chem 1996; 271: 1770–1775.
Sahuquillo AG, Roumier A, Teixeiro E, Bragado R, Alarcon B . T cell receptor (TCR) engagement in apoptosis-defective, but interleukin 2 (IL-2)-producing, T cells results in impaired ZAP70/CD3-zeta association. J Exp Med 1998; 187: 1179–1192.
Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17: 2426–2434.
Corcoran M, Parker A, Orchard J, Davis Z, Wirtz M, Schmitz OJ et al. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 2005; 90: 1078–1088.
Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan XJ et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002; 99: 4087–4093.
Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G . Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003; 101: 1087–1093, [Eub 2002 Sep 1026].
Scielzo C, Ghia P, Conti A, Bachi A, Guida G, Geuna M et al. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest 2005; 115: 1644–1650.
Acknowledgements
CS is a recipient of a scholarship from FIRC, Milano. We are grateful to Ms Rose Mary Carletti for her precious technical assistance and to Dr Michela Frenquelli for her continuous support in the lab work. We are indebted with Alessandro Ambrosi, Eliana La Ferrara e Giuseppe Guida for their precious advice on statistical analysis. This work was supported in part by Associazione Italiana per la Ricerca sul Cancro (AIRC), Progetto Oncologia CNR-MIUR, MURST 40%, the CLL Global Research Foundation, Ministero della Sanità (R.F.2002, no. 183), Fondazione CARIPLO and MIUR-Firb (RBNE01LNX7-006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scielzo, C., Camporeale, A., Geuna, M. et al. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia 20, 689–695 (2006). https://doi.org/10.1038/sj.leu.2404138
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404138
Keywords
- ZAP-70
- B lymphocytes
- B-lymphoid malignancies
- chronic lymphocytic leukemia
This article is cited by
-
Profiling of human lymphocytes reveals a specific network of protein kinases modulated by endurance training status
Scientific Reports (2020)
-
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia
Leukemia (2011)
-
Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia
Leukemia (2010)
-
Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division
Leukemia (2008)
-
HS1 complexes with cytoskeleton adapters in normal and malignant chronic lymphocytic leukemia B cells
Leukemia (2007)